Sanofi Aventis sees no Plavix copy despite FDA
PARIS Jan 17 (Reuters) - French drugs group Sanofi-Aventis (SASY.PA) said on Thursday it did not expect Indian generics group Dr Reddy's Laboratories Ltd. (REDY.BO) to launch a copy of its blood thinning product Plavix.
A Sanofi spokesman said that as a court injunction was in force against a generic version of Plavix launched by Apotex the launch of another copy was "highly improbable".
The U.S. Food and Drug Administration said on Wednesday it had approved pills containing clopidogrel bisulfate, the active ingredient in Plavix, made by Dr Reddy's.
(Reporting by Noelle Mennella; Editing by Paul Bolding)
((nicholas.antonovics@reuters.com; +33149495182; Reuters messaging: nicholas.antonovics.reuters.com@reuters.net)) Keywords: SANOFIAVENTIS PLAVIX/
(C) Reuters 2008. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nL1738598
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters